Coenzyme Q supplementation in pulmonary arterial hypertension

Abstract

Mitochondrial dysfunction is a fundamental abnormality in the vascular endothelium and smooth muscle of patients with pulmonary arterial hypertension (PAH). Because coenzyme Q (CoQ) is essential for mitochondrial function and efficient oxygen utilization as the electron carrier in the inner mitochondrial membrane, we hypothesized that CoQ would improve mitochondrial function and benefit PAH patients. To test this, oxidized and reduced levels of CoQ, cardiac function by echocardiogram, mitochondrial functions of heme synthesis and cellular metabolism were evaluated in PAH patients (N=8) in comparison to healthy controls (N=7), at baseline and after 12 weeks oral CoQ supplementation. CoQ levels were similar among PAH and control individuals, and increased in all subjects with CoQ supplementation. PAH patients had higher CoQ levels than controls with supplementation, and a tendency to a higher reduced-to-oxidized CoQ ratio. Cardiac parameters improved with CoQ supplementation, although 6-minute walk distances and BNP levels did not significantly change. Consistent with improved mitochondrial synthetic function, hemoglobin increased and red cell distribution width (RDW) decreased in PAH patients with CoQ, while hemoglobin declined slightly and RDW did not change in healthy controls. In contrast, metabolic and redox parameters, including lactate, pyruvate and reduced or oxidized gluthathione, did not change in PAH patients with CoQ. In summary, CoQ improved hemoglobin and red cell maturation in PAH, but longer studies and/or higher doses with a randomized placebo-controlled controlled design are necessary to evaluate the clinical benefit of this simple nutritional supplement.

Ubiquinol Ameliorates Endothelial Dysfunction in Subjects with Mild-to-Moderate Dyslipidemia: A Randomized Clinical Trial

“…Although the role of CoQ10 has extensively been explored in healthy subjects and in different pathological conditions, its effects on EF have mainly been described in patients with CVD and related chronic states such as type 2 diabetes and CAD [46,47]. In a study involving CoQ10 supplementation in healthy non-smokers with hypercholesterolemia, Raitakari et al found baseline FMD values that were comparable to those observed in our population, lending support to the notion that hypercholesterolemia alone is sufficient to induce ED in the absence of other risk factors.…”

Combined effects of guanidinoacetic acid, coenzyme Q10 and taurine on growth performance, gene expression and ascites mortality in broiler chickens

“…In the interim, CoQ 10 alone or with combination of TAU plunged ascites mortality to levels even lower that the control. There is a great deal of evidence on the role of CoQ 10 in cardiometabolic disorders (Zozina, Covantev, Goroshko, Krasnykh, & Kukes, 2018) and pulmonary arterial hypertension (Sharp et al, 2014;Yousefi, Khajali, Hassanpour, & Khajali, 2013) through improved mitochondria function and enhanced NO production.…”

The Acute Effect of the Antioxidant Drug U-74389G on Red Blood Cell Distribution Width Levels During Hypoxia Reoxygenation Injury in Rats

“…Isik T et al 20 have shown RDW levels as an independent correlate predictor index of adverse outcomes also associated with both presence and severity of isolated ischemia than baseline RDW levels measured at ischemic patients and controls. Sharp J et al 21 considered mitochondrial dysfunction as a fundamental abnormality in the vascular endothelium and smooth muscle of patients with pulmonary arterial hypertension (PAH). Coenzyme Q (CoQ) is essential for mitochondrial function and effi cient oxygen utilization as the electron carrier in the inner mitochondrial membrane.…”